Sign Up to like & get
recommendations!
1
Published in 2018 at "American Journal of Hematology"
DOI: 10.1002/ajh.25238
Abstract: Glasdegib is a Hedgehog pathway inhibitor. This ongoing, open‐label, phase 2 study (NCT01546038) evaluated glasdegib plus cytarabine/daunorubicin in patients with untreated acute myeloid leukemia (AML) or high‐risk myelodysplastic syndromes (MDS). Patients received glasdegib 100 mg…
read more here.
Keywords:
cytarabine daunorubicin;
high risk;
aml high;
phase study ... See more keywords